My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 205

    1.

    Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in medical inpatients.

    McGarry LJ, Stokes ME, Thompson D.

    Thromb J. 2006 Sep 27;4:17.PMID: 17005045 [PubMed]Related articlesFree article

    2.

    Retrospective database analysis of the prevention of venous thromboembolism with low-molecular-weight heparin in acutely III medical inpatients in community practice.

    McGarry LJ, Thompson D.

    Clin Ther. 2004 Mar;26(3):419-30. Review.PMID: 15110135 [PubMed - indexed for MEDLINE]Related articles

    3.

    Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.

    Kanaan AO, Silva MA, Donovan JL, Roy T, Al-Homsi AS.

    Clin Ther. 2007 Nov;29(11):2395-405. Review.PMID: 18158080 [PubMed - indexed for MEDLINE]Related articles

    4.

    Clinical and economic outcomes in patients at risk of venous thromboembolism receiving appropriate enoxaparin or unfractionated heparin prophylaxis.

    Amin AN, Lin J, Lenhart G, Schulman KL.

    Thromb Haemost. 2009 Aug;102(2):321-6.PMID: 19652883 [PubMed - indexed for MEDLINE]Related articles

    5.

    Enoxaparin. A pharmacoeconomic appraisal of its use in thromboembolic prophylaxis after total hip arthroplasty.

    Dunn CJ, Goa KL.

    Pharmacoeconomics. 1996 Aug;10(2):179-90.PMID: 10163420 [PubMed - indexed for MEDLINE]Related articles

    6.

    Enoxaparin in the treatment of deep vein thrombosis with or without pulmonary embolism: an individual patient data meta-analysis.

    Mismetti P, Quenet S, Levine M, Merli G, Decousus H, Derobert E, Laporte S.

    Chest. 2005 Oct;128(4):2203-10.PMID: 16236875 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Cost effectiveness of enoxaparin as prophylaxis against venous thromboembolic complications in acutely ill medical inpatients: modelling study from the hospital perspective in Germany.

    Schädlich PK, Kentsch M, Weber M, Kämmerer W, Brecht JG, Nadipelli V, Huppertz E.

    Pharmacoeconomics. 2006;24(6):571-91.PMID: 16761905 [PubMed - indexed for MEDLINE]Related articles

    8.

    Thromboprophylaxis in medically ill patients at risk for venous thromboembolism.

    Burleigh E, Wang C, Foster D, Heller S, Dunn D, Safavi K, Griffin B, Smith J.

    Am J Health Syst Pharm. 2006 Oct 15;63(20 Suppl 6):S23-9.PMID: 17032931 [PubMed - indexed for MEDLINE]Related articles

    9.

    Comparison of the two-year outcomes and costs of prophylaxis in medical patients at risk of venous thromboembolism.

    Deitelzweig SB, Becker R, Lin J, Benner J.

    Thromb Haemost. 2008 Nov;100(5):810-20.PMID: 18989525 [PubMed - indexed for MEDLINE]Related articles

    10.

    Thromboprophylaxis in medical patients: the role of low-molecular-weight heparin.

    Turpie AG, Norris TM.

    Thromb Haemost. 2004 Jul;92(1):3-12. Review.PMID: 15213839 [PubMed - indexed for MEDLINE]Related articles

    11.

    Hospital-based costs associated with venous thromboembolism treatment regimens.

    Merli G, Ferrufino C, Lin J, Hussein M, Battleman D.

    J Thromb Haemost. 2008 Jul;6(7):1077-86. Epub 2008 Jul 1.PMID: 18445118 [PubMed - indexed for MEDLINE]Related articles

    12.

    An open-label, comparative study of the efficacy and safety of once-daily dose of enoxaparin versus unfractionated heparin in the treatment of proximal lower limb deep-vein thrombosis.

    Ramacciotti E, Araújo GR, Lastoria S, Maffei FH, Karaoglan de Moura L, Michaelis W, Sandri JL, Dietrich-Neto F; CLETRAT Investigators.

    Thromb Res. 2004;114(3):149-53.PMID: 15342210 [PubMed - indexed for MEDLINE]Related articles

    13.

    Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients.

    McGarry LJ, Thompson D, Weinstein MC, Goldhaber SZ.

    Am J Manag Care. 2004 Sep;10(9):632-42.PMID: 15515996 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.

    Holzheimer RG.

    Eur J Med Res. 2004 Apr 30;9(4):225-39. Review.PMID: 15210403 [PubMed - indexed for MEDLINE]Related articles

    15.

    Low-molecular-weight heparin versus unfractionated heparin in the treatment of patients with acute pulmonary thromboembolism.

    Findik S, Erkan ML, Selçuk MB, Albayrak S, Atici AG, Doru F.

    Respiration. 2002;69(5):440-4.PMID: 12232452 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    An economic evaluation of the costs and benefits of heparin rationalisation in a hospital pharmacy.

    Reeves P, Cooke J, Lloyd A, Hutchings A.

    Pharm World Sci. 2004 Jun;26(3):160-8.PMID: 15230364 [PubMed - indexed for MEDLINE]Related articles

    17.

    Assessing, preventing, and treating venous thromboembolism: evidence-based approaches.

    Nutescu EA.

    Am J Health Syst Pharm. 2007 Jun 1;64(11 Suppl 7):S5-13. Review.PMID: 17519445 [PubMed - indexed for MEDLINE]Related articles

    18.

    Pharmacological venous thromboembolism prophylaxis in hospitalized medical patients: a meta-analysis of randomized controlled trials.

    Wein L, Wein S, Haas SJ, Shaw J, Krum H.

    Arch Intern Med. 2007 Jul 23;167(14):1476-86.PMID: 17646601 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Bemiparin: a review of its use in the prevention of venous thromboembolism and treatment of deep vein thrombosis.

    Chapman TM, Goa KL.

    Drugs. 2003;63(21):2357-77. Review.PMID: 14524738 [PubMed - indexed for MEDLINE]Related articles

    20.

    Enoxaparin: a review of its use as thromboprophylaxis in acutely ill, nonsurgical patients.

    Siddiqui MA, Wagstaff AJ.

    Drugs. 2005;65(7):1025-36. Review.PMID: 15892594 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity